Brickell Biotech Inc. [NASDAQ: BBI] stock went on an upward path that rose over 47.64% on Wednesday, amounting to a one-week price increase of more than 41.80%. The company report on May 19, 2022 that Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases –.
– Topline results from the SAD and MAD parts of the Phase 1 study expected to be announced by early 2023 –.
Over the last 12 months, BBI stock dropped by -81.51%. The one-year Brickell Biotech Inc. stock forecast points to a potential upside of 84.26. The average equity rating for BBI stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $20.11 million, with 119.38 million shares outstanding and 117.85 million shares in the current float. Compared to the average trading volume of 5.60M shares, BBI stock reached a trading volume of 163551267 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Brickell Biotech Inc. [BBI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBI shares is $1.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBI stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Lake Street have made an estimate for Brickell Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 28, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on August 25, 2020, representing the official price target for Brickell Biotech Inc. stock.
The Average True Range (ATR) for Brickell Biotech Inc. is set at 0.02, with the Price to Sales ratio for BBI stock in the period of the last 12 months amounting to 40.23. The Price to Book ratio for the last quarter was 1.32, with the Price to Cash per share for the same quarter was set at 0.15.
BBI Stock Performance Analysis:
Brickell Biotech Inc. [BBI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 41.80. With this latest performance, BBI shares gained by 7.84% in over the last four-week period, additionally sinking by -26.50% over the last 6 months – not to mention a drop of -81.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBI stock in for the last two-week period is set at 58.42, with the RSI for the last a single of trading hit 68.89, and the three-weeks RSI is set at 52.22 for Brickell Biotech Inc. [BBI]. The present Moving Average for the last 50 days of trading for this stock 0.1870, while it was recorded at 0.1311 for the last single week of trading, and 0.3117 for the last 200 days.
Insight into Brickell Biotech Inc. Fundamentals:
Brickell Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.
Brickell Biotech Inc. [BBI] Insider Position Details
There are presently around $1 million, or 16.10% of BBI stock, in the hands of institutional investors. The top three institutional holders of BBI stocks are: VANGUARD GROUP INC with ownership of 3,112,092, which is approximately 14.803% of the company’s market cap and around 0.40% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 1,905,124 shares of the stock with an approximate value of $0.22 million in BBI stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.17 million in BBI stock with ownership of nearly -53.232% of the company’s market capitalization.
Positions in Brickell Biotech Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 9 institutional holders increased their position in Brickell Biotech Inc. [NASDAQ:BBI] by around 460,877 shares. Additionally, 15 investors decreased positions by around 3,122,297 shares, while 11 investors held positions by with 5,555,761 shares. The mentioned changes placed institutional holdings at 9,138,935 shares, according to the latest SEC report filing. BBI stock had 1 new institutional investments in for a total of 17 shares, while 8 institutional investors sold positions of 837,687 shares during the same period.